Jaguar Health Secures $16M Upfront License Payment, Q4 EPS Tops Estimates
Jaguar Health reported Q4 2025 EPS of -$0.36, beating consensus by nearly $3.90 while net revenue of $3.2 million fell short of estimates and rose 5% sequentially. In January 2026 it secured a $16 million upfront non-dilutive license payment from Future Pak and is appealing a Nasdaq bid-price noncompliance ruling.
1. Q4 2025 Financial Performance
Jaguar Health reported Q4 2025 EPS of -$0.36 versus consensus of -$4.26 and net revenue of $3.2 million, representing a 5% sequential increase but an 8% decline from Q4 2024.
2. Full-Year 2025 Results
For the full year, net product revenue was $11.5 million, roughly flat year-over-year; loss from operations widened to $45.9 million, net loss attributable to common stockholders increased to $53.6 million, and non-GAAP EBITDA loss was $48.2 million.
3. Strategic Licensing Deal
In January 2026 Jaguar Health secured a $16 million upfront non-dilutive payment under its U.S. license with Future Pak for crofelemer-based products Mytesi and Canalevia-CA1, with an additional $2 million due upon post-closing conditions and $3 million received toward $20 million in potential milestones.
4. Nasdaq Listing Appeal
The company appealed a Nasdaq Listing Rule 5550(a)(2) noncompliance notice after its bid price closed below $1.00 for 30 consecutive business days; a hearing is scheduled for April 7, 2026, staying any delisting action, and an investor webcast is set for April 10, 2026 at 8:30 a.m. ET.